ET-02
/ EdiGene
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 17, 2023
A Study of ET-02 in Patients With Relapsed or Refractory B-cell Malignancy(NHL/ALL)
(clinicaltrials.gov)
- P=N/A | N=18 | Active, not recruiting | Sponsor: EdiGene (GuangZhou) Inc. | Recruiting ➔ Active, not recruiting
Enrollment closed • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology • CD19
1 to 1
Of
1
Go to page
1